Caladrius Biosciences Company Profile (NASDAQ:CLBS)

About Caladrius Biosciences

Caladrius Biosciences logoCaladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company's product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company's T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLBS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.89
  • 50 Day Moving Average: $5.14
  • 200 Day Moving Average: $6.00
  • 52-Week Range: $4.00 - $15.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.28
  • P/E Growth: -0.01
  • Market Cap: $N/A
  • Beta: 1.08
Profitability:
  • Net Margins: -220.23%
  • Return on Equity: -163.53%
  • Return on Assets: -53.49%
Debt:
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.31%
  • Quick Ratio: 1.31%
Additional Links:
Companies Related to Caladrius Biosciences:

Analyst Ratings

Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $3.44 (28.83% downside)

Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetDetails
9/7/2016HC WainwrightReiterated RatingBuyView Rating Details
8/23/2016Chardan CapitalInitiated CoverageBuy$6.50View Rating Details
5/14/2016Maxim GroupReiterated RatingHoldView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyView Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
9/24/2015WBB SecuritiesReiterated RatingBuy$7.00View Rating Details
8/7/2015Benchmark Co.DowngradeBuy -> Hold$12.00 -> $2.00View Rating Details
4/6/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details
1/9/2015Oppenheimer Holdings Inc.Initiated CoverageOutperform$10.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.31)$4.70 millionViewN/AView Earnings Details
3/2/2015($0.42)($0.32)ViewN/AView Earnings Details
11/3/2014($0.41)($0.44)ViewN/AView Earnings Details
8/11/2014($0.28)($0.38)ViewN/AView Earnings Details
5/8/2014($0.40)($0.49)ViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
Current Year EPS Consensus Estimate: $-6.17 EPS
Next Year EPS Consensus Estimate: $-3.77 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 79.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Caladrius Biosciences (NASDAQ:CLBS)
DateHeadline
finance.yahoo.com logoCaladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune - Yahoo Finance (NASDAQ:CLBS)
finance.yahoo.com - September 20 at 10:04 AM
globenewswire.com logoCaladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune - GlobeNewswire (press release) (NASDAQ:CLBS)
globenewswire.com - September 19 at 5:01 PM
globenewswire.com logoCaladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune (NASDAQ:CLBS)
globenewswire.com - September 19 at 8:58 AM
4-traders.com logoCaladrius Biosciences : Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants (NASDAQ:CLBS)
www.4-traders.com - September 16 at 4:09 PM
streetinsider.com logoCaladrius Biosciences (CLBS) Raises $25M Through Private Placements - StreetInsider.com (NASDAQ:CLBS)
www.streetinsider.com - September 15 at 9:40 PM
finance.yahoo.com logoCaladrius Bio Jumps on Private Placement Deal (NASDAQ:CLBS)
finance.yahoo.com - September 15 at 4:37 PM
publicnow.com logoCaladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants (NASDAQ:CLBS)
www.publicnow.com - September 15 at 10:52 AM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi (NASDAQ:CLBS)
biz.yahoo.com - September 15 at 10:52 AM
News IconAnalysts Place Caladrius Biosciences Inc (NASDAQ:CLBS) Under ... - Post News (NASDAQ:CLBS)
www.kentuckypostnews.com - September 12 at 9:01 AM
News IconSell-side is Weighing in on Caladrius Biosciences Inc (NASDAQ:CLBS) Earnings & Targets - Frisco Fastball (NASDAQ:CLBS)
friscofastball.com - September 10 at 8:54 AM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming September Conferences (NASDAQ:CLBS)
finance.yahoo.com - September 8 at 4:08 PM
finance.yahoo.com logoCaladrius Biosciences Completes Enrollment of First Patient Cohort in Phase 2 Trial of CLBS03 to Treat Type 1 Diabetes (NASDAQ:CLBS)
finance.yahoo.com - September 6 at 9:06 AM
finance.yahoo.com logoCoverage initiated on Caladrius Biosciences by Chardan Capital Markets (NASDAQ:CLBS)
finance.yahoo.com - August 23 at 4:22 PM
live-pr.com logoNew Market Research Report: Caladrius Biosciences, Inc. (CLBS) - Financial and Strategic SWOT Analysis Review (NASDAQ:CLBS)
www.live-pr.com - August 19 at 11:36 AM
News IconStock Slipping Lower in Session: Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Post News (NASDAQ:CLBS)
www.kentuckypostnews.com - August 17 at 9:40 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CLBS)
biz.yahoo.com - August 9 at 5:14 PM
publicnow.com logoCaladrius Biosciences Reports 2016 Second Quarter Financial Results (NASDAQ:CLBS)
www.publicnow.com - August 9 at 5:14 PM
ftsenews.co.uk logoCaladrius Biosciences, Inc. (CLBS) Updated Price Targets - FTSE News (NASDAQ:CLBS)
www.ftsenews.co.uk - August 5 at 4:17 PM
nasdaq.com logoCaladrius Biosciences to Host 2016 Second Quarter Financial Results Conference Call on August 9 at (NASDAQ:CLBS)
www.nasdaq.com - August 2 at 9:02 AM
publicnow.com logoCaladrius Biosciences to Host 2016 Second Quarter Financial Results Conference Call on August 9 at 5:00 pm Eastern Time (NASDAQ:CLBS)
www.publicnow.com - August 2 at 9:02 AM
streetinsider.com logoCaladrius Biosciences (CLBS) Gains Amid FDA Fast Track Designation for CLBS03 for Type 1 Diabetes - StreetInsider.com (NASDAQ:CLBS)
www.streetinsider.com - July 29 at 8:04 AM
streetinsider.com logoCaladrius Biosciences (CLBS) Gains Amid FDA Fast Track Designation for CLBS03 for Type 1 Diabetes (NASDAQ:CLBS)
www.streetinsider.com - July 28 at 12:46 PM
publicnow.com logoCaladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes (NASDAQ:CLBS)
www.publicnow.com - July 28 at 7:48 AM
finance.yahoo.com logo7:31 am Caladrius Biosciences announce CLBS03 was granted Fast Track designation by the FDA for the treatment of type 1 diabetes mellitus (NASDAQ:CLBS)
finance.yahoo.com - July 28 at 7:31 AM
publicnow.com logoCaladrius Biosciences Announces 1-for-10 Reverse Split (NASDAQ:CLBS)
www.publicnow.com - July 27 at 9:08 AM
News IconEquity Roundup: Stock Performance Focus on Caladrius Biosciences Inc (NASDAQ:CLBS) - Press Telegraph (NASDAQ:CLBS)
presstelegraph.com - July 23 at 8:31 AM
news.cmlviz.com logoCaladrius Biosciences Inc (NASDAQ:CLBS) Stock Technicals at Critical Inflection Point - CML News (NASDAQ:CLBS)
news.cmlviz.com - July 22 at 11:57 AM
capitalcube.com logoETF’s with exposure to Caladrius Biosciences, Inc. : July 21, 2016 (NASDAQ:CLBS)
www.capitalcube.com - July 21 at 1:52 PM
news.cmlviz.com logoCaladrius Biosciences, Inc. (NasdaqCM:CLBS) Fundamental Star Rating Report - CML News (NASDAQ:CLBS)
news.cmlviz.com - July 20 at 11:55 AM
fiscalstandard.com logoBroker Outlook For Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard (NASDAQ:CLBS)
www.fiscalstandard.com - July 20 at 11:55 AM
News IconCaladrius Biosciences Inc (NASDAQ:CLBS) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:CLBS)
telanaganapress.com - July 18 at 4:27 PM
ftsenews.co.uk logoNew Broker Ratings For Caladrius Biosciences, Inc. (CLBS) - FTSE News (NASDAQ:CLBS)
www.ftsenews.co.uk - July 15 at 12:31 PM
news.cmlviz.com logoCaladrius Biosciences Inc Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:CLBS)
news.cmlviz.com - July 14 at 9:39 AM
News IconCaladrius Biosciences Inc (NASDAQ:CLBS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CLBS)
www.engelwooddaily.com - July 13 at 9:38 PM
News IconTime to Sell Caladrius Biosciences Inc After The Completion of This Bearish Multiple Bottom Chart Pattern? - Consumer Eagle (NASDAQ:CLBS)
www.consumereagle.com - July 12 at 8:29 AM
News IconCan Caladrius Biosciences Inc (NASDAQ:CLBS) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:CLBS)
www.engelwooddaily.com - July 7 at 12:02 PM
fiscalstandard.com logoCaladrius Biosciences, Inc. (CLBS) Current Analyst Ratings - Fiscal Standard (NASDAQ:CLBS)
www.fiscalstandard.com - July 7 at 12:02 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming July Conferences - GlobeNewswire (press release) (NASDAQ:CLBS)
globenewswire.com - July 7 at 12:02 PM
publicnow.com logoCaladrius Biosciences to Present at Upcoming July Conferences (NASDAQ:CLBS)
www.publicnow.com - July 7 at 7:31 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard (NASDAQ:CLBS)
www.fiscalstandard.com - July 5 at 8:58 AM
News IconCheck on Unusual Volume for: Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Engelwood Daily (NASDAQ:CLBS)
www.engelwooddaily.com - June 30 at 9:42 PM
News IconCaladrius Biosciences Incorporated (NASDAQ:CLBS) Shorts Decreased by 30.43% After Short Covering - Engelwood Daily (NASDAQ:CLBS)
www.engelwooddaily.com - June 29 at 9:19 PM
News IconCovering the Bases on Caladrius Biosciences Inc (NASDAQ:CLBS): Where is the Stock Going? - Press Telegraph (NASDAQ:CLBS)
presstelegraph.com - June 29 at 12:22 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CLBS)
biz.yahoo.com - June 27 at 5:02 PM
publicnow.com logoCaladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine (NASDAQ:CLBS)
www.publicnow.com - June 27 at 7:41 AM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CLBS)
biz.yahoo.com - June 23 at 4:51 PM
globenewswire.com logoCaladrius Subsidiary, PCT, to Manufacture Phase 3 Cell Therapy Product for Kiadis Pharma (NASDAQ:CLBS)
globenewswire.com - June 22 at 8:58 AM
capitalcube.com logoETF’s with exposure to Caladrius Biosciences, Inc. : June 20, 2016 (NASDAQ:CLBS)
www.capitalcube.com - June 20 at 2:13 PM
fiscalstandard.com logoThis Weeks Broker Views For Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard (NASDAQ:CLBS)
www.fiscalstandard.com - June 19 at 4:03 PM
News IconCaladrius Biosciences Inc (NASDAQ:CLBS) Stock Update & Estimates - Stock Tick Tock (NASDAQ:CLBS)
www.stockticktock.com - June 3 at 10:21 PM

Social

Caladrius Biosciences (NASDAQ:CLBS) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff